Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients

This study has been completed.
Sponsor:
Collaborator:
AIDS Clinical Trials Group
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00082498
First received: May 11, 2004
Last updated: July 22, 2014
Last verified: July 2014
  Purpose

New treatment options are critical for treatment-experienced HIV infected patients with drug resistance. HIV entry inhibitors have been shown effective in patients with resistance to other anti-HIV drugs. This study will test the safety and effectiveness of three different doses of vicriviroc (formerly known as Schering D, SCH-D, or SCH 417690) in HIV infected patients.


Condition Intervention Phase
HIV Infections
Drug: SCH-D (vicriviroc)
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Phase II, Randomized, Double-Blind Study of the Safety and Efficacy of Vicriviroc (An Orally Administered HIV-1 Entry Inhibitor) in HIV-Infected, Treatment-Experienced Subjects

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:
  • Change in HIV-1 viral load [ Time Frame: From baseline to Day 14 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety and tolerability [ Time Frame: Throughout the study ] [ Designated as safety issue: Yes ]
  • Virologic and immunologic outcomes [ Time Frame: Throughout the study ] [ Designated as safety issue: No ]
  • Clinical outcomes [ Time Frame: Throughout the study ] [ Designated as safety issue: No ]
  • Pharmacokinetic outcomes [ Time Frame: At Weeks 2 and 8 ] [ Designated as safety issue: No ]
  • Viral coreceptor phenotype [ Time Frame: At study entry, Day 4, and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, and 48 ] [ Designated as safety issue: No ]
  • Adherence measures [ Time Frame: At study entry and Weeks 2, 8, 16, 24, 32, 40, and 48 ] [ Designated as safety issue: No ]

Enrollment: 119
Study Start Date: May 2004
Study Completion Date: January 2011
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
Group 1 will receive placebo
Drug: Placebo
Patients in Group 1 will receive placebo.
Experimental: 2
Group 2 will receive 5 mg vicriviroc daily
Drug: SCH-D (vicriviroc)
Group 2 will receive 5 mg vicriviroc daily; Group 3 will receive 10 mg vicriviroc daily; and Group 4 will receive 15 mg vicriviroc daily. If at or after Week 16 a participant's viral load has not met certain criteria, a dose increase of vicriviroc may occur and the participant will enter Step 2. As of 10/12/05, patients in Group 2 and any patients who entered Step 2 following virologic failure in Step 1 will be unblinded and offered either 15 mg vicriviroc daily through this study or the option of seeking alternative treatment.
Experimental: 3
Group 3 will receive 10 mg vicriviroc daily
Drug: SCH-D (vicriviroc)
Group 2 will receive 5 mg vicriviroc daily; Group 3 will receive 10 mg vicriviroc daily; and Group 4 will receive 15 mg vicriviroc daily. If at or after Week 16 a participant's viral load has not met certain criteria, a dose increase of vicriviroc may occur and the participant will enter Step 2. As of 10/12/05, patients in Group 2 and any patients who entered Step 2 following virologic failure in Step 1 will be unblinded and offered either 15 mg vicriviroc daily through this study or the option of seeking alternative treatment.
Experimental: 4
Group 4 will receive 15 mg vicriviroc daily
Drug: SCH-D (vicriviroc)
Group 2 will receive 5 mg vicriviroc daily; Group 3 will receive 10 mg vicriviroc daily; and Group 4 will receive 15 mg vicriviroc daily. If at or after Week 16 a participant's viral load has not met certain criteria, a dose increase of vicriviroc may occur and the participant will enter Step 2. As of 10/12/05, patients in Group 2 and any patients who entered Step 2 following virologic failure in Step 1 will be unblinded and offered either 15 mg vicriviroc daily through this study or the option of seeking alternative treatment.

Detailed Description:

Vicriviroc is an oral HIV-1 entry inhibitor that targets the CCR5 receptor of T cells. Vicriviroc has been shown safe, well-tolerated, and active in Phase I clinical trials in treatment-naive HIV infected patients. The goal of this study is to evaluate the antiretroviral activity of three dose levels of vicriviroc in HIV infected, treatment-experienced patients who are failing their current ritonavir-containing antiretroviral therapy (ART).

The study will last at least 48 weeks, but no more than 5 years. There are 3 steps in this study. Patients will be randomly assigned to one of 4 groups. Group 1 will receive placebo; Group 2 will receive 5 mg vicriviroc daily; Group 3 will receive 10 mg vicriviroc daily; and Group 4 will receive 15 mg vicriviroc daily. If at or after Week 16 a participant's viral load has not met certain criteria, a dose increase of vicriviroc may occur and the participant will enter Step 2. As of 10/12/05, patients in Group 2 and any patients who entered Step 2 following virologic failure in Step 1 will be unblinded and offered either 15 mg vicriviroc daily through this study or the option of seeking alternative treatment. All patients will continue their current ART (not provided by the study). After two weeks, patients will receive ART optimized by the results of genotypic/phenotypic testing performed at study screening. All participants who have received or are receiving vicriviroc will enter Step 3 and be followed for an additional 4 years. Participants who complete the study may be eligible to receive vicriviroc through a rollover study sponsored by Schering-Plough, the drug's manufacturer.

Physical exams and blood collection will occur at study entry, Day 4, and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, and 48. Additionally, blood will be drawn twice, at least 2 hours apart, at both Weeks 2 and 8 for vicriviroc pharmacokinetic analysis. Patients will undergo an electrocardiogram (EKG) at Weeks 2, 8, 24, and 48. Patients will be assessed for peripheral neuropathy at study entry and Weeks 24 and 48, and will be asked to complete an adherence questionnaire at entry and Weeks 2, 8, 16, 24, 32, 40, and 48. For Step 3 participants undergoing follow-up, physical exams and blood work will occur every 6 months for 4 years.

Five participants currently enrolled at four sites that are no longer receiving funding and who will not be transferred or redirected to a site within their proximity will be subject to the following changes. There will no longer be follow-up visits per the schedule of events described in the protocol. Instead, participants will have their follow-up limited to self-report through telephone interviews to ascertain vital status, occurrence of malignancies (if any), and collection of information such as HIV-1 RNA and CD4 cell count. For these participants only, the HIV-1 RNA and CD4 cell count will be done as part of the participant's clinical care and will not be paid for by the study. The follow-up telephone interviews will be conducted at six-month intervals using the script provided by the study team.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Note: This study was closed to screening on 09/20/05 and to enrollment on 10/20/05.

Inclusion Criteria for Step 1:

  • HIV infected
  • Experiencing virologic failure on current ART regimen
  • Current ART regimen contains ritonavir (100 to 800 mg/day) and has been stable for at least 8 weeks prior to study entry. If amprenavir or fosamprenavir is part of the regimen, 200 to 800 mg/day ritonavir must be used for at least 2 weeks prior to study entry.
  • Experienced virologic failure on at least one ART regimen containing 3 or more drugs prior to current failing regimen
  • CD4 count of 50 cells/mm3 or more within 6 weeks prior to study entry
  • HIV viral load of 5,000 copies/ml or more within 6 weeks prior to study entry
  • HIV strain of R5-only phenotype within 6 weeks prior to study entry
  • Willing to use acceptable forms of contraception
  • Able and willing to adhere to study dose and visit schedules

Inclusion Criteria for Step 2:

  • HIV viral load not suppressed by at least 1log10 below baseline viral load by Week 16 or after
  • QTc interval on EKG less than 500 msec, and less than 60 msec increase from baseline within 14 days of Step 2 entry

Inclusion Criteria for Step 3:

  • Use of vicriviroc in Step 1 or 2 of this study or the Schering rollover study. Participants who are currently not taking vicriviroc are eligible.

Exclusion Criteria for Step 1:

  • Hepatitis C antibody and RNA positive
  • Hepatitis B surface antigen positive
  • Efavirenz or nevirapine use within 8 weeks of study entry
  • Vaccination within 2 weeks prior to study screening
  • Investigational agents within 30 days prior to study entry
  • Systemic cancer chemotherapy or other systemic cytotoxic agents within 30 days prior to study entry
  • Immunosuppressants within 30 days prior to study entry. Systemic corticosteroids at replacement doses (10 mg/day prednisone or less) are not excluded.
  • Immunomodulators within 30 days prior to study entry
  • Considered at risk for seizure: history of seizure, recent history of head trauma with loss of consciousness, central nervous system (CNS) tumors, or other CNS problems that, in the opinion of the investigator, pose increased risk for seizure
  • Medications to prevent seizures or with the potential to cause seizures within 30 days prior to study entry
  • Allergy to SCH 417690 or its components
  • Alcohol or drug abuse that, in the opinion of the investigator, would interfere with the study
  • Serious illness requiring systemic treatment or hospitalization. A patient who is clinically stable on therapy is not excluded.
  • Any clinically significant disease or condition that, in the opinion of the investigator, may interfere with the study
  • Require certain medications
  • Pregnancy or breastfeeding

Exclusion Criteria for Step 2:

  • Have X4 or X4/R5 tropic virus, as determined by the HIV-1 coreceptor tropism assay
  • Intend to use efavirenz or nevirapine in background ART regimen
  • Allergy to vicriviroc or its formulations
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00082498

  Show 30 Study Locations
Sponsors and Collaborators
AIDS Clinical Trials Group
Investigators
Study Chair: Roy M. Gulick, MD, MPH Cornell HIV Clinical Trials Unit
Study Chair: Charles Flexner, MD Johns Hopkins University Hospital
Study Chair: Daniel Kuritzkes, MD Harvard Medical School, Partners AIDS Research Center
  More Information

Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00082498     History of Changes
Other Study ID Numbers: A5211, 10097, ACTG A5211, 5-K24-AI051966-03
Study First Received: May 11, 2004
Last Updated: July 22, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
SCH-D
Schering D
Treatment Experienced
Entry Inhibitors
Fusion Inhibitors
Vicriviroc

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
RNA Virus Infections
Retroviridae Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases

ClinicalTrials.gov processed this record on November 24, 2014